SCHEMBL3883487

SCHEMBL3883487

O=C(O)CCc1ccc(OCCOc2ccccc2Cl)c(-c2ccc3[nH]ccc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 10/20 0.48
FFAR4 Q5NUL3 4/20 0.47
LTB4R Q15722 1/20 0.44
ENPP2 Q13822 1/20 0.43
PTGER1 P34995 1/20 0.41
PTGER4 P35408 1/20 0.41
PTGER3 P43115 1/20 0.41
PTGER2 P43116 1/20 0.41
PPARG P37231 2/20 0.41
PPARA Q07869 1/20 0.41
TP53 P04637 1/20 0.40
MDM2 Q00987 1/20 0.40
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885517 0.91 FFAR1 (0.49) FFAR1FFAR4LTB4RENPP2PTGER1
SCHEMBL3885515 0.90 ALDH1A1 (0.43) FFAR1FFAR4ENPP2ALDH1A1SMN1; SMN2
SCHEMBL3886458 0.89 FFAR4 (0.52) FFAR1FFAR4LTB4RENPP2PTGER1
SCHEMBL27607994 0.88 ENPP2 (0.48) FFAR1FFAR4LTB4RENPP2PPARG
SCHEMBL3883544 0.88 FFAR4 (0.59) FFAR1FFAR4ENPP2PTGER1PTGER4
SCHEMBL3882776 0.87 FFAR1 (0.49) FFAR1FFAR4LTB4RENPP2PPARG
SCHEMBL3882144 0.86 PTGER1 (0.52) FFAR1FFAR4LTB4RENPP2PTGER1
SCHEMBL3882225 0.86 FFAR1 (0.48) FFAR1FFAR4LTB4RPPARGPPARA
SCHEMBL3884999 0.86 FFAR1 (0.49) FFAR1FFAR4LTB4RENPP2PPARG
SCHEMBL3880827 0.86 FFAR1 (0.49) FFAR1FFAR4LTB4RENPP2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR1 13/4885FFAR4 115/4885LTB4R 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.